IL15 and eosinophilic esophagitis: CALY-002 is an anti-IL-15 mAb, and it is currently under study to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with EoE or celiac disease (ClinicalTrials.gov Identifier: NCT04593251) [74].